Centocor
Centocor is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Centocor.
Centocor is a company.
Key people at Centocor.
Key people at Centocor.
Centocor was a pioneering biotechnology company founded in 1979, specializing in monoclonal antibody technology for diagnostics and therapeutics, particularly for autoimmune diseases, cancer, and inflammatory conditions.[1][2][3][4] Best known for developing Remicade (infliximab), a blockbuster drug approved for Crohn's disease, rheumatoid arthritis, and other indications, it initially focused on diagnostic assays before expanding into high-impact therapeutics like ReoPro and oncology drugs such as Doxil.[1][3][4] The company served patients with chronic illnesses through innovative biologics, solving unmet needs in immunology and gastroenterology, and achieved significant growth, employing 1,500 by 1992 with production facilities in the US and Europe, before its $4.9 billion acquisition by Johnson & Johnson in 1999.[1][2][4]
Centocor emerged in May 1979 from the vision of Dutch-born biochemist Hubert J.P. Schoemaker and entrepreneur Michael Wall, inspired by early biotech breakthroughs like monoclonal antibodies.[1][2][4][5] Wall left Flow Laboratories to lead a team of scientists aiming to commercialize diagnostics, partnering with institutions like the Wistar Institute under immunologist Hilary Koprowski.[2][5] Schoemaker chaired the company until the J&J acquisition.[1] Early traction came from licensing antibody-based diagnostic tests, such as an ovarian cancer assay sold to Abbott in 1981, fueling growth through collaborations that expanded from 15 in 1985 to 80 by 1990.[2][5] A pivotal setback was the 1992-1993 failure of Centoxin, its first solo therapeutic for sepsis, which halted trials due to adverse events and nearly collapsed the firm, but survival via diagnostics cash reserves ($150 million) enabled rebounds with ReoPro approval in 1994 and Remicade's 1998 launch.[2][4]
Centocor rode the 1970s-1980s biotech revolution, capitalizing on monoclonal antibody discoveries to bridge diagnostics and therapeutics amid rising demand for targeted treatments for sepsis, cancer, and autoimmune diseases like Crohn's and rheumatoid arthritis.[1][2][5] Timing was ideal post-1970s breakthroughs, with market forces like annual sepsis costs ($10 billion, 100,000 US deaths) and unmet immunology needs favoring its model.[4][5] It influenced the ecosystem by proving biotech viability—surviving failures like Centoxin via diversified revenue—paving the way for J&J's biotech expansion (e.g., Ortho Biotech in 1990) and inspiring licensing-heavy strategies in modern biopharma.[2][3][4]
Post-1999 acquisition, Centocor integrated into J&J's Janssen Biotech (rebranded ~2011), amplifying Remicade's legacy while evolving into broader immunology and oncology portfolios.[3][4] Biosimilars and patent cliffs challenged Remicade sales, but J&J's resources drove successors in gastroenterology, rheumatology, and dermatology. Looking ahead, Centocor's foundational mAb expertise positions Janssen amid trends like personalized medicine, ADCs, and AI-drug discovery, potentially expanding influence in immune-oncology. Its story—from scrappy diagnostics pioneer to J&J powerhouse—exemplifies biotech's high-risk path to transformative impact, reminding investors that resilience amid setbacks defines enduring leaders in lifesciences.
